Biohaven Pharmaceuticals (BHVN) Gains Following Sales Surge for Migraine Drug NURTEC ODT

Biohaven Pharmaceutical Holding (BHVN) PT Raised to $130 at Cowen on Nurtec Momentum

Cowen analyst Ken Cacciatore raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $130.00 (from $90.00) while maintaining an Outperform rating.

The analyst commented, "Preliminary Nurtec revenues reached $93MM in Q2, substantially above our and the Street's $55MM. Although we are unsure... More

Pre-Open Stock Movers 07/07: (DARE) (OPNT) (BHVN) Higher; (BSQR) (IDYA) (LOAN) Lower (more...)

Pre-Open Stock Movers:

Dare Bioscience (NASDAQ: DARE) 58.9% HIGHER; entered into an agreement with the Bill & Melinda Gates Foundation, under which we were awarded a new grant of up to $48.95 million (the Grant) to support the development of DARE-LARC1, our investigational user-controlled, long-acting reversible contraceptive.

Opiant Pharmaceuticals, Inc.(NASDAQ: OPNT) 34.5% HIGHER; Announced positive top-line results from its confirmatory pharmacokinetic study for OPNT003, nasal nalmefene, for opioid overdose.

Bsquare (NASDAQ: BSQR)... More

Biohaven Pharma (BHVN) Q2 NURTEC ODT Sales Rise to $93M

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced preliminary net product revenue of NURTEC ODT (rimegepant) for the second quarter of 2021.

Based on preliminary unaudited financial information, the Company reported $93 million in net product revenue from sales of NURTEC ODT in the second quarter of 2021. Total prescriptions of NURTEC ODT from product launch to date (as of June 30, 2021) were over 750,000, with approximately 38,000 unique prescribers.

The foregoing information reflects the Company's estimate with respect to net product revenue for NURTEC ODT based on currently available information, which is preliminary and unaudited, is not a... More